Advent International, a global private equity firm, agreed to acquire a 50.01% stake in Suven Pharmaceuticals, a pharmaceutical company, for $762m. "We are delighted to bring Advent into Suven Pharma as a strategic investor. We have built a business with industry-leading growth and margins...Their experience and resources will launch the next phase of growth for Suven pharma. This move will benefit Suven platform immensely. The proposed collaboration with Cohance is a win-win for Suven and its public shareholders," Venkateswarlu Jasti, Suven Pharmaceuticals Managing Director.